Participated · Grant · Feb 2026

QT Sense is a Netherlands-based life-science technology company building a precision quantum sensing platform that enables more accurate biological insights for drug discovery and spatial biology applications. The platform is positioned as an enabling layer that can expand what is measurable and actionable in complex biological systems, potentially unlocking a multi-billion-euro market opportunity. With its newly funded “AAA strategy,” the company plans a dual focus: accelerating user adoption in pharmaceutical settings while simultaneously deepening the platform’s technical capabilities and scaling manufacturing for production-quality delivery. This marks a transition from pilot projects to repeatable customer deployments. QT Sense frames the round not merely as capital but as a milestone toward a “quantum future” for life sciences, emphasizing alignment with investors on long-term vision and near-term commercialization priorities. No operating metrics such as revenue or user counts were disclosed in the article.

Participated · Seed · Jul 2021

QuantWare develops modular quantum processors built on its proprietary VIO architecture and has introduced the VIO-40K design aimed at higher qubit capacity. The company produces commercially available quantum processing units at industrial scale and follows an open approach that allows third parties to build and integrate their own designs. QuantWare was founded by researchers from QuTech and is expanding manufacturing capability in Europe through KiloFab, a dedicated facility in the Netherlands. Following its €152 million Series B, the company plans to scale both processor development and industrial production. Management frames these steps as accelerating the transition of quantum computing from research toward large-scale commercial deployment.